Jim Simons Innoviva, Inc. Transaction History

Renaissance Technologies LLC

$70.6 Billion
Q2 2025

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Innoviva, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 4,760,832 shares of INVA stock, worth $95.6 Million. This represents 0.14% of its overall portfolio holdings.

Number of Shares

4,760,832

Previous 4,557,232 4.47%

Holding current value

$95.6 Million

Previous $82.6 Million 15.76%

% of portfolio

0.14%

Previous 0.13%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 13, 2025	BUY	$17.1 - $21.8 $3.48 Million - $4.44 Million	203,600 Added 4.47%	4,760,832 $95.6 Million
Q1 2025 May 14, 2025	BUY	$17.21 - $18.98 $5.09 Million - $5.61 Million	295,500 Added 6.93%	4,557,232 $82.6 Million
Q4 2024 Feb 13, 2025	SELL	$17.35 - $20.32 $1.18 Million - $1.39 Million	-68,175 Reduced 1.57%	4,261,732 $73.9 Million
Q3 2024 Nov 13, 2024	BUY	$16.33 - $20.04 $65,319 - $80,160	4,000 Added 0.09%	4,329,907 $83.6 Million
Q2 2024 Aug 09, 2024	SELL	$14.4 - $16.4 $568,800 - $647,800	-39,500 Reduced 0.9%	4,325,907 $70.9 Million
Q1 2024 May 13, 2024	BUY	$14.56 - $16.78 $3.22 Million - $3.71 Million	220,960 Added 5.33%	4,365,407 $66.5 Million
Q4 2023 Feb 13, 2024	BUY	$12.32 - $16.27 $1.79 Million - $2.36 Million	145,040 Added 3.63%	4,144,447 $66.5 Million
Q3 2023 Nov 14, 2023	BUY	$12.37 - $13.89 $1.86 Million - $2.09 Million	150,560 Added 3.91%	3,999,407 $52 Million
Q2 2023 Aug 11, 2023	SELL	$11.39 - $13.72 $812,107 - $978,236	-71,300 Reduced 1.82%	3,848,847 $49 Million
Q1 2023 May 12, 2023	SELL	$10.73 - $13.6 $3.32 Million - $4.21 Million	-309,460 Reduced 7.32%	3,920,147 $44.1 Million
Q4 2022 Feb 13, 2023	SELL	$11.8 - $13.78 $425,578 - $496,989	-36,066 Reduced 0.85%	4,229,607 $56 Million
Q3 2022 Nov 14, 2022	SELL	$11.61 - $15.22 $6.19 Million - $8.12 Million	-533,300 Reduced 11.11%	4,265,673 $49.5 Million
Q2 2022 Aug 12, 2022	SELL	$14.32 - $19.88 $5.94 Million - $8.24 Million	-414,660 Reduced 7.95%	4,798,973 $70.8 Million
Q1 2022 May 13, 2022	SELL	$15.39 - $20.25 $1.25 Million - $1.65 Million	-81,500 Reduced 1.54%	5,213,633 $101 Million
Q4 2021 Feb 11, 2022	SELL	$15.91 - $18.72 $2.38 Million - $2.8 Million	-149,309 Reduced 2.74%	5,295,133 $91.3 Million
Q3 2021 Nov 12, 2021	SELL	$13.06 - $17.24 $5.65 Million - $7.46 Million	-433,000 Reduced 7.37%	5,444,442 $91 Million
Q2 2021 Aug 13, 2021	SELL	$11.45 - $13.96 $19.5 Million - $23.8 Million	-1,705,200 Reduced 22.49%	5,877,442 $78.8 Million
Q1 2021 May 13, 2021	SELL	$11.06 - $12.87 $3.31 Million - $3.85 Million	-299,160 Reduced 3.8%	7,582,642 $90.6 Million
Q4 2020 Feb 10, 2021	SELL	$9.33 - $12.48 $4.78 Million - $6.4 Million	-512,809 Reduced 6.11%	7,881,802 $97.7 Million
Q3 2020 Nov 13, 2020	SELL	$10.33 - $14.49 $1.41 Million - $1.97 Million	-136,200 Reduced 1.6%	8,394,611 $87.7 Million
Q2 2020 Aug 13, 2020	BUY	$11.49 - $15.26 $3.75 Million - $4.99 Million	326,800 Added 3.98%	8,530,811 $119 Million
Q1 2020 May 14, 2020	BUY	$8.11 - $15.23 $2.52 Million - $4.73 Million	310,314 Added 3.93%	8,204,011 $96.5 Million
Q4 2019 Feb 13, 2020	BUY	$10.28 - $14.38 $3.21 Million - $4.49 Million	312,010 Added 4.12%	7,893,697 $112 Million
Q3 2019 Nov 13, 2019	BUY	$10.05 - $14.55 $5.35 Million - $7.74 Million	532,079 Added 7.55%	7,581,687 $79.9 Million
Q2 2019 Aug 12, 2019	BUY	$13.1 - $14.95 $7.92 Million - $9.03 Million	604,320 Added 9.38%	7,049,608 $103 Million
Q1 2019 May 14, 2019	BUY	$13.69 - $20.06 $4.55 Million - $6.67 Million	332,580 Added 5.44%	6,445,288 $90.4 Million
Q4 2018 Feb 13, 2019	BUY	$13.96 - $18.26 $85.3 Million - $112 Million	6,112,708 New	6,112,708 $107 Million

Others Institutions Holding INVA

# of Institutions

281

Shares Held

80.3M

Call Options Held

10.3K

Put Options Held

161K

View Full List

About Innoviva, Inc.

Ticker INVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,706,000
Market Cap $1.4B
Description
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...

More about INVA

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account